L453-0300 Screening compound: 4-[3-(2-{methyl[(3-methylphenyl)carbamoyl]amino}ethyl)-1,2,4-oxadiazol-5-yl]-N-[(pyridin-2-yl)methyl]benzamide

L453-0300 Screening compound: 4-[3-(2-{methyl[(3-methylphenyl)carbamoyl]amino}ethyl)-1,2,4-oxadiazol-5-yl]-N-[(pyridin-2-yl)methyl]benzamide
L453-0300 Screening compound: 4-[3-(2-{methyl[(3-methylphenyl)carbamoyl]amino}ethyl)-1,2,4-oxadiazol-5-yl]-N-[(pyridin-2-yl)methyl]benzamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L453-0300
4-[3-(2-{methyl[(3-methylphenyl)carbamoyl]amino}ethyl)-1,2,4-oxadiazol-5-yl]-N-[(pyridin-2-yl)methyl]benzamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L453-0300

Molecular Formula

C26H26N6O3 (C26 H26 N6 O3)

Compound Name

4-[3-(2-{methyl[(3-methylphenyl)carbamoyl]amino}ethyl)-1,2,4-oxadiazol-5-yl]-N-[(pyridin-2-yl)methyl]benzamide

IUPAC name

4-[3-(2-{methyl[(3-methylphenyl)carbamoyl]amino}ethyl)-124-oxadiazol-5-yl]-N-[(pyridin-2-yl)methyl]benzamide

SMILES

Cc1cccc(NC(N(C)CCc2noc(-c(cc3)ccc3C(NCc3ncccc3)=O)n2)=O)c1

InChI

InChI=1S/C26H26N6O3/c1-18-6-5-8-21(16-18)29-26(34)32(2)15-13-23-30-25(35-31-23)20-11-9-19(10-12-20)24(33)28-17-22-7-3-4-14-27-22/h3-12,14,16H,13,15,17H2,1-2H3,(H,28,33)(H,29,34)

InChI Key

CIQISPFCWACJGH-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27253154

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

470.53

Hydrogen Bond Acceptors Count

8.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

11.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

3.373

Distribution Coefficient, logD

3.373

Water Solubility, LogSw

-3.63

Polar Surface Area

91.812

Acid Dissociation Constant (pKa)

11.58

Base Dissociation Constant (pKb)

3.36

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

19.20

L453-0300 in Drug Discovery

Included in Screening Libraries

Serine Proteases Inhibitors Library (32732 compounds)

Adenosine Receptors Targeted Library (19896 compounds)

Akt-Targeted Library (14764 compounds)

Histone Deacetylases (HDAC) Targeted Library (9760 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Cardiovascular
  • Skin
  • Metabolic
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Nervous system
  • Eye
  • Cardiovascular
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Cancer
  • Nervous system
  • Hemic and lymphatic
  • Endocrine
  • Immune system
Targets:
  • Proteases
  • GPCR
  • Kinases
Mechanism of action:
  • Receptor's ligands
  • Epigenetic

References: we are preparing a list of scientific research reports with L453-0300 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L453-0300?
Check Price and Availability of L453-0300, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L453-0300 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L453-0300
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L453-0300
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L453-0300 available by request